Journal article

Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC

center dot Antiretroviral protease inhibitors such as lopinavir and saquinavir have been shown to be substrates of ABCB1. Co-administration with the potent ABCB1 and CYP3A4 inhibitor, ritonavir, has shown improved pharmacokinetics and subsequent therapeutic effects of protease inhibitors. Darunavir is a recently licensed protease inhibitor with potent antiretroviral effects but has yet to be characterized as a potential substrate for drug transporters.


Related material